2006
A phase II trial of docetaxel plus carboplatin in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel chemotherapy: Preliminary results
Oh W, Manola J, Ross R, Berkowitz A, Ryan C, Eilers K, Beer T. A phase II trial of docetaxel plus carboplatin in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel chemotherapy: Preliminary results. Journal Of Clinical Oncology 2006, 24: 14533-14533. DOI: 10.1200/jco.2006.24.18_suppl.14533.Peer-Reviewed Original ResearchHormone refractory prostate cancerPhase II trialDocetaxel chemotherapyHormone refractory prostate cancer patientsPhase II trial of docetaxelMedian time to progressionDocetaxel-based therapyTrial of docetaxelRefractory prostate cancerTime to progressionDocetaxel-based chemotherapyEfficacy of docetaxel chemotherapyStaging of patientsBaseline performance statusCarboplatin AUCHRPC patientsMedian PSAPSA declineRECIST criteriaMedian survivalNeuroendocrine differentiationII trialMedian agePerformance statusProstate cancerResponse to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes
Oh W, Manola J, Babcic V, Harnam N, Kantoff P. Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. Urology 2006, 67: 1235-1240. PMID: 16765185, DOI: 10.1016/j.urology.2006.01.006.Peer-Reviewed Original ResearchConceptsProgression-free survivalTaxane-based chemotherapySecond-line chemotherapyOverall survivalProstate cancerProstate-Specific Antigen Working GroupResponse to second-line chemotherapyMedian prostate-specific antigenMedian progression-free survivalHormone refractory prostate cancerHormone-refractory prostate cancerDiagnosis to chemotherapyMedian patient ageRefractory prostate cancerTaxane-based treatmentProstate-specific antigenDocetaxel chemotherapyTaxane-basedChemotherapy regimensProstate-specificSurvival benefitPatient ageChemotherapyRetrospective analysisClinical trials
2005
CO4 A COMPARISON OF LOGISTIC REGRESSION AND COX PROPORTIONAL HAZARDS MODELS FOR IDENTIFICATION OF RISK FACTORS FOR RENAL IMPAIRMENT IN HORMONE REFRACTORY PROSTATE CANCER (HRPC) PATIENTS WITH BONE METASTASES (BM) TREATED WITH ZOLEDRONIC ACID (ZA)
Oh W, Proctor K, Nakabayashi M, Evan C, Tormey L, Breierova L, Smith M, Neary M, Duh. CO4 A COMPARISON OF LOGISTIC REGRESSION AND COX PROPORTIONAL HAZARDS MODELS FOR IDENTIFICATION OF RISK FACTORS FOR RENAL IMPAIRMENT IN HORMONE REFRACTORY PROSTATE CANCER (HRPC) PATIENTS WITH BONE METASTASES (BM) TREATED WITH ZOLEDRONIC ACID (ZA). Value In Health 2005, 8: a16-a17. DOI: 10.1016/s1098-3015(10)67190-2.Peer-Reviewed Original ResearchHormone refractory prostate cancerZoledronic acidCox proportional hazards modelsProportional hazards modelProstate cancerRisk factorsHazards modelLogistic regressionResponse to second-line chemotherapy in patients with hormone refractory prostate cancer (HRPC) receiving two sequences of mitoxantrone (M) and taxanes (T)
Oh W, Manola J, Babcic V, Harnam N, Kantoff P. Response to second-line chemotherapy in patients with hormone refractory prostate cancer (HRPC) receiving two sequences of mitoxantrone (M) and taxanes (T). Journal Of Clinical Oncology 2005, 23: 4616-4616. DOI: 10.1200/jco.2005.23.16_suppl.4616.Peer-Reviewed Original ResearchHormone refractory prostate cancerResponse to second-line chemotherapyRefractory prostate cancerSecond-line chemotherapyProstate cancerChemotherapyTaxanesMitoxantrone
2004
AN OVERVIEW OF CHEMOTHERAPY TRIALS IN LOCALIZED AND RECURRENT NONMETASTATIC PROSTATE CANCER
Oh W. AN OVERVIEW OF CHEMOTHERAPY TRIALS IN LOCALIZED AND RECURRENT NONMETASTATIC PROSTATE CANCER. Journal Of Urology 2004, 172: s34-s37. PMID: 15535440, DOI: 10.1097/01.ju.0000141674.92253.fe.Peer-Reviewed Original ResearchConceptsHormone refractory diseaseProstate cancerLocal therapyRefractory diseaseClinical trialsFeasibility of administering chemotherapyProstate cancer disease statesState of prostate cancerHormone refractory prostate cancerHigh riskDefinitive local therapyDefinitive local treatmentStudies evaluating chemotherapyRecurrent prostate cancerLocalized prostate cancerRefractory prostate cancerNonmetastatic prostate cancerPhase III trialsRisk of recurrenceCancer disease statesAndrogen-dependent diseasesMedline literature reviewAntigenic stateRandomized clinical trialsNeoadjuvant settingA phase I study of estramustine, weekly docetaxel and carboplatin (EDC) chemotherapy in patients with hormone refractory prostate cancer (HRPC)
Oh W, Hagmann E, Manola J, George D, Gilligan T, Smith M, Kaufman D, Kantoff P. A phase I study of estramustine, weekly docetaxel and carboplatin (EDC) chemotherapy in patients with hormone refractory prostate cancer (HRPC). Journal Of Clinical Oncology 2004, 22: 4656-4656. DOI: 10.1200/jco.2004.22.14_suppl.4656.Peer-Reviewed Original ResearchHormone refractory prostate cancerRefractory prostate cancerPhase I studyProstate cancerDocetaxelCarboplatinChemotherapyEstramustineDocetaxel plus carboplatin (DC) may have significant activity in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel-based chemotherapy
Tay M, George D, Gilligan T, Kelly S, Appleby L, Taplin M, Febbo P, Kantoff P, Oh W. Docetaxel plus carboplatin (DC) may have significant activity in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel-based chemotherapy. Journal Of Clinical Oncology 2004, 22: 4679-4679. DOI: 10.1200/jco.2004.22.14_suppl.4679.Peer-Reviewed Original ResearchHormone refractory prostate cancerRefractory prostate cancerDocetaxel-based chemotherapyProstate cancerDocetaxelChemotherapyA phase I study of estramustine, weekly docetaxel and carboplatin (EDC) chemotherapy in patients with hormone refractory prostate cancer (HRPC)
Oh W, Hagmann E, Manola J, George D, Gilligan T, Smith M, Kaufman D, Kantoff P. A phase I study of estramustine, weekly docetaxel and carboplatin (EDC) chemotherapy in patients with hormone refractory prostate cancer (HRPC). Journal Of Clinical Oncology 2004, 22: 4656-4656. DOI: 10.1200/jco.2004.22.90140.4656.Peer-Reviewed Original ResearchHormone refractory prostate cancerRefractory prostate cancerPhase I studyProstate cancerDocetaxelCarboplatinChemotherapyEstramustineDocetaxel plus carboplatin (DC) may have significant activity in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel-based chemotherapy
Tay M, George D, Gilligan T, Kelly S, Appleby L, Taplin M, Febbo P, Kantoff P, Oh W. Docetaxel plus carboplatin (DC) may have significant activity in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel-based chemotherapy. Journal Of Clinical Oncology 2004, 22: 4679-4679. DOI: 10.1200/jco.2004.22.90140.4679.Peer-Reviewed Original ResearchHormone refractory prostate cancerRefractory prostate cancerDocetaxel-based chemotherapyProstate cancerDocetaxelChemotherapy
2003
The Evolving Role of Chemotherapy and Other Systemic Therapies for Managing Localized Prostate Cancer
Oh W. The Evolving Role of Chemotherapy and Other Systemic Therapies for Managing Localized Prostate Cancer. Journal Of Urology 2003, 170: s28-s34. PMID: 14610407, DOI: 10.1097/01.ju.0000095356.02647.64.Peer-Reviewed Original ResearchConceptsLocalized prostate cancerProstate cancerSystemic therapyLocalized diseaseClinical trialsClinical stage T3 diseaseHigh-risk localized diseaseSerum prostate specific antigenHormone refractory prostate cancerHigh riskBiopsy Gleason scoreStage T3 diseaseStudies evaluating chemotherapyRefractory prostate cancerAdvanced prostate cancerMolecular targeted agentsProstate specific antigenMedline literature reviewNeoadjuvant settingGleason scoreT3 diseaseMetastatic diseaseCytotoxic chemotherapyLocal therapyAdjuvant chemotherapy
1998
MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS
OH W, KANTOFF P. MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS. Journal Of Urology 1998, 160: 1220-1229. PMID: 9751323, DOI: 10.1016/s0022-5347(01)62501-1.Peer-Reviewed Original ResearchConceptsTreatment of hormone refractory prostate cancerHormone refractory prostate cancerRefractory prostate cancerBiology of hormone refractory prostate cancerSecondary hormonal therapyProstate cancerHormone therapyProstate specific antigen valuesAntiandrogen withdrawal responsePhase II studyMeasurement of response to therapyResponse to therapyClinical trial endMeasure response to treatmentResponse to treatmentMEDLINE literature searchCombination of drugsClinical trial interpretationAvailability of agentsAlternative antiandrogenEstramustine combinationsPalliative capabilitiesClinical responsePalliative benefitII studyMANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER
OH W, KANTOFF P. MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER. Journal Of Urology 1998, 160: 1220-1229.. DOI: 10.1097/00005392-199810000-00003.Peer-Reviewed Original ResearchTreatment of hormone refractory prostate cancerHormone refractory prostate cancerRefractory prostate cancerBiology of hormone refractory prostate cancerSecondary hormonal therapyProstate cancerHormone therapyProstate specific antigen valuesAntiandrogen withdrawal responsePhase II studyMeasurement of response to therapyResponse to therapyClinical trial endResponse to treatmentMeasure response to treatmentMEDLINE literature searchCombination of drugsClinical trial interpretationAvailability of agentsAlternative antiandrogenEstramustine combinationsPalliative capabilitiesClinical responsePalliative benefitII study
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply